Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.60 |
| ▸ | CTSS | P25774 | 3/20 | 0.55 |
| ▸ | CTSK | P43235 | 2/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.55 |
| ▸ | KLK7 | P49862 | 1/20 | 0.55 |
| ▸ | REN | P00797 | 8/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.51 |
| ▸ | CTSD | P07339 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27487264 | 1.00 | KLK5 (0.60) | KLK5CTSSCTSKCTSLCTSB | |
| SCHEMBL30375069 | 1.00 | KLK5 (0.60) | KLK5CTSSCTSKCTSLCTSB | |
| SCHEMBL27489033 | 0.96 | KLK5 (0.56) | KLK5CTSSCTSKCTSLCTSB | |
| SCHEMBL7294995 | 0.95 | CTSS (0.56) | KLK5CTSSCTSKCTSLCTSB | |
| SCHEMBL16667823 | 0.92 | KLK5 (0.64) | KLK5CTSSCTSKCTSLCTSB | |
| SCHEMBL27510152 | 0.92 | CTSS (0.53) | KLK5CTSSCTSKCTSLCTSB | |
| SCHEMBL12890824 | 0.91 | CTSS (0.52) | KLK5CTSSCTSKCTSLCTSB | |
| SCHEMBL7205174 | 0.91 | REN (0.61) | KLK5CTSSCTSKCTSLCTSB | |
| SCHEMBL5303963 | 0.90 | ALDH1A1 (0.61) | CTSSCTSKCTSLCTSBREN | |
| SCHEMBL8245888 | 0.90 | ALDH1A1 (0.61) | CTSSCTSKCTSLCTSBREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673912-B2 | Continuous, solvent-free and non-enzymatic peptide synthesis by reactive extrusion | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2023-06-13 | — | — | US | disclosed |
| US-20210115085-A1 | CONTINUOUS, SOLVENT-FREE AND NON-ENZYMATIC PEPTIDE SYNTHESIS BY REACTIVE EXTRUSION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-04-22 | — | — | US | disclosed |
| EP-3527580-B1 | CONTINUOUS, SOLVENT-FREE AND NON-ENZYMATIC PEPTIDE SYNTHESIS BY REACTIVE EXTRUSION | CENTRE NAT RECH SCIENT (FR) | 2021-04-07 | — | — | EP | disclosed |
| CN-111868069-A | Continuous, solvent-free and non-enzymatic peptide synthesis by reactive extrusion | 国家科学研究中心(CNRS) | 2020-10-30 | — | — | CN | disclosed |
| EP-3527580-A1 | CONTINUOUS, SOLVENT-FREE AND NON-ENZYMATIC PEPTIDE SYNTHESIS BY REACTIVE EXTRUSION | Centre National de la Recherche Scientifique CNRS (FR) | 2019-08-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115085-A1 | CONTINUOUS, SOLVENT-FREE AND NON-ENZYMATIC PEPTIDE SYNTHESIS BY REACTIVE EXTRUSION | QPCT, ANPEP, PEPD | KLK5 2786/4885CTSS 1548/4885CTSK 1529/4885 |
| US-11673912-B2 | Continuous, solvent-free and non-enzymatic peptide synthesis by reactive extrusion | QPCT, ANPEP, PEPD | KLK5 2786/4885CTSS 1548/4885CTSK 1529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.